December 16, 2014—Westminster, Some 80 percent of liver cancer patients have inoperable tumors. Now 41 percent of the hospitals ranked best overall in the latest U.S. News & World Best Hospitals edition, and 42 percent of best cancer care hospitals use the technologically advanced Surefire Infusion System (SIS) from Surefire Medical for minimally invasive direct-to-tumor treatment alternatives: radioembolization and chemoembolization.

“First, I find it to be effective in preventing reflux,” says Dr. Eric Reiner, Associate Professor of Diagnostic Radiology at the Yale School of Medicine and an Interventional Radiologist at Yale-New Haven Hospital, a best cancer hospital. “Just as important, I find it to be really excellent in improving tumor uptake of the embolic agents in Drug Eluting Bead (DEB) and Transarterial Chemo Embolization (TACE) procedures.”

Liver cancer is the third most common cause of cancer deaths worldwide, with 2.2 million cases. In the U.S. liver cancer deaths doubled between 1981 and 2010, from eight to 16.3 deaths per 100,000, according to the Centers for Disease Control and Prevention (CDC).

The growing preference for the novel Surefire Infusion System with its telescoping tip reflects results of a growing body of published data showing evidence of:

  • Far greater penetration of dose into tumors
  • A 70 percent reduction in fluoroscopy exposure
  • Up to 50 percent reduction in procedure time.

“That the nation’s top-rated hospitals have so quickly come to prefer the performance of the Surefire Infusion System clearly substantiates our device’s growing market leadership in interventional procedures,” says Surefire Medical President and CEO James E. Chomas.

About Surefire Medical

Surefire Medical, Inc., based in Westminster, Colo., was founded in 2009 to develop innovative infusion systems for the Interventional Radiology and Interventional Oncology markets. Surefire’s infusion systems are designed to precisely deliver embolic agents through a unique microcatheter with an expandable tip that collapses in forward flow and dynamically expands to the vessel wall in reverse flow in order to maximize targeted delivery, minimize reflux and reduce damage to healthy tissue. The Surefire Infusion System has received regulatory approval in the U.S., Europe, Canada, Australia, New Zealand and Taiwan.


Clinical Data Shows Surefire Technology Achieved 79% Objective Response versus 37% Using a Standard Microcatheter in Treating Primary Liver Cancer. Study presented at SIR 2017 Annual Scientific Meeting.